Abstracts tagged "glucocorticoids"

Abstract Number: 587 • 2015 ACR/ARHP Annual Meeting
Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Cindy Strehl¹, Johannes W J Bijlsma², Maarten de Wit³, Maurizio Cutolo⁴, Raphaele Seror⁵, Kevin L. Winthrop⁶, Frank Buttgereit¹ and EULAR Task Force on Glucocorticoids, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁵Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ⁶Division of Infectious Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Glucocorticoids (GC) are used to treat a wide range of inflammatory diseases including rheumatic and musculoskeletal diseases. EULAR recommendations on GC therapy are up…
Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting
Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Nataliya Milman⁸, Jacqueline Peck⁹, Judy A. Shea¹⁰, Peter F. Cronholm⁴ and Peter A. Merkel¹¹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²NONE, Branbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹NONE, Oxford, United Kingdom, ¹⁰Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…
Abstract Number: 1220 • 2015 ACR/ARHP Annual Meeting
Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Rachel J Black^1,2, Rebecca M Joseph^3,4, Mohammad Movahedi², Mark Lunt² and William G Dixon^2,5, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁵Manchester Academic Health Sciences Centre, Health e-Research Centre, Farr Institute for Health Informatics Research, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Oral glucocorticoids (GCs) are commonly used in the treatment of rheumatoid arthritis (RA). Although GPs don’t typically alter DMARD prescriptions, changes to GC therapy…
Abstract Number: 1118 • 2014 ACR/ARHP Annual Meeting
Olecranon Bursitis Is Often Hemorrhagic and Responds to Steroid Injections
Kyriakos A. Kirou¹ and Naveed Chaudhry², ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose . Olecranon bursitis is a common presentation to an outpatient rheumatology practice. The differential diagnosis includes crystalline bursitis (gout and pseudogout), inflammatory bursitis due…
Abstract Number: 919 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65
Akhila Balasubramanian¹, Sally Wade², Robert A Adler³, Celia Fang (Lin)⁴, Michael Maricic⁵, Cynthia O'Malley¹, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Wade Outcomes Research and Consulting, Salt Lake City, UT, ³Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, ⁴Amgen, Thousand Oaks, CA, ⁵Catalina Pointe Rheumatology, Tucson, AZ, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Systemic glucocorticoid use can increase fracture risk, although dose-specific effects are not well understood, especially in younger adults. Underlying diseases (e.g., rheumatoid arthritis [RA])…
Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting
Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
Abstract Number: 29 • 2014 ACR/ARHP Annual Meeting
Impaired Bone Healing in Patients Suffering from Rheumatoid Arthritis – Anti-Inflammatory Therapy As Confounder
Annemarie Lang¹, Sarah Fuegener², Paula Hoff², Anastasia Rakow³, Manuela Jakstadt⁴, Timo Gaber⁴, Gerd Burmester², Carsten Perka³ and Frank Buttgereit⁵, ¹Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Center for Musculoskeletal Surgery, Orthopedic Department, Charité University Medicine, Berlin, Germany, ⁴Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany, ⁵Charité University Hospital, Berlin, Germany
Background/Purpose Anti-inflammatory treatment of rheumatoid arthritis (RA) with glucocorticoids (GC) and/or non-steroidal anti-inflammatory drugs (NSAIDs) is supposed to negatively influence bone metabolism and healing. It…
Abstract Number: L13 • 2014 ACR/ARHP Annual Meeting
Monthly Ibandronate Reduces Bone Loss in Osteopenic Women with Rheumatoid Arthritis Receiving Long-Term Glucocorticoids: A 48-Week Double-Blinded Randomized Placebo-Controlled Investigator-Initiated Trial
Kichul Shin¹, Sung-Hwan Park², Won Park³, Han Joo Baek⁴, Yun Jong Lee⁵, Seong-Wook Kang⁶, Jung-Yoon Choe⁷, Wan-Hee Yoo⁸, Yong-Beom Park⁹, Jung-Soo Song¹⁰, Bin Yoo¹¹, Dae-Hyun Yoo¹² and Yeong Wook Song¹³, ¹Rheumatology, SMG-SNU Boramae Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁶Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁷Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁸Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹⁰Rheumatology, Chung-Ang Univ Hospital, Seoul, South Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ¹²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹³Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Long-term use of glucocorticoids (GC) is problematic for patients with increased risk for vertebral fractures, especially those with rheumatoid arthritis (RA). Thus, prevention of…
Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…
Abstract Number: 2375 • 2014 ACR/ARHP Annual Meeting
Should Physician Reduce patients’ Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics?
Huifeng Yun¹, Lang Chen², George W. Reed³, Joel M. Kremer⁴, Jeffrey D. Greenberg⁵ and Jeffrey R. Curtis⁶, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Corrona, LLC., Southborough, MA, ⁴Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁵Rheumatology, New York University School of Medicine, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Glucocorticoids (GCs) and biologic disease-modifying antirheumatic drugs (DMARDs) have previously been associated with serious infection events (SIEs) among rheumatoid arthritis (RA) patients. For patients…
Abstract Number: 2225 • 2014 ACR/ARHP Annual Meeting
Does Previous Corticosteroid Treatment Affect the Inflammatory Infiltrate Found in Polymyositis Muscle Biopsies?
Mayara Mendes Pinhata¹, Juliana Jesus do Nascimento¹, Suely Kazue Nagahashi Marie² and Samuel Katsuyuki Shinjo¹, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: We conducted this study because there have been no studies evaluating the effect of the use of corticosteroids (CE) on the presence of inflammatory…
Abstract Number: 2093 • 2014 ACR/ARHP Annual Meeting
Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone-Related Suppression of Type I Interferon Response Gene Expression
Tamarah D. de Jong¹, Saskia Vosslamber¹, Marjolein Blits¹, Gertjan Wolbink², Michael T. Nurmohamed^2,3, Connie J. van der Laken⁴, Gerrit Jansen⁵, Alexandre E. Voskuyl⁵ and Cornelis L. Verweij⁶, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁶Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Elevated type I IFN response gene (IRG) expression has been described to be clinically relevant in predicting the non-response to rituximab in rheumatoid arthritis…
Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Shih-Yin Chen¹, Chan-Bum Choi^2,3,4, Qian Li⁵, Wei-Shi Yeh¹, Yuan-Chi Lee⁶, Amy H Kao¹ and Matthew H. Liang⁷, ¹Biogen Idec, Cambridge, MA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Section of Rheumatology, VA Healthcare System, Boston, MA, ⁴Department of Aging, Brigham and Women's Hospital, Boston, MA, ⁵Evidera, Lexington, MA, ⁶Formerly of Evidera, Lexington, MA, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…
Abstract Number: 1420 • 2014 ACR/ARHP Annual Meeting
Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR
Salvador Loredo-Alanís¹, David Vega-Morales², Mario Garza-Elizondo¹, Mario Garcia-Pompermayer³, Roberto Negrete-López¹, Daniel Treviño-Montes¹ and Diana Flores-Alvarado², ¹Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ³Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterey, Mexico
Background/Purpose The clinical evaluation of Rheumatoid arthritis (RA) is accomplished with compound indexes allowing better clinical decision. Clinical remission nowadays is an attainable target in…
Abstract Number: 1211 • 2014 ACR/ARHP Annual Meeting
Gene Expression Profile in Muscle Tissue before and after Immunosuppressive Treatment in Patients with Myositis
Joan Raouf¹, Ingela M. Loell², Yi-Wen Chen³, Rongye Shi⁴, Inger Nennesmo⁵, Helene Alexanderson⁶, Maryam Dastmalchi², Marina Korotkova⁷, Kanneboyina Nagaraju^8,9 and Ingrid E. Lundberg^10,11, ¹Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA., Washington DC, DC, ⁴Research Center for Genetic Medicine, Childrens National Medical Center, Research Center for Genetic Medicine, Washington DC, USA, Washington DC, WA, ⁵Institution for Laboratory Medicine (LABMED), Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden, Stockholm, Sweden, ⁶Karolinska Institutet, Department of medicine, Rheumatology Unit, Karolinska Universitetssjukhuset Solna, Stockholm, Sweden, Stockholm, Sweden, ⁷Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁸Genetic Medicine, Children's National Medical Center, Washinton D C, DC, ⁹Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, ¹⁰Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ¹¹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Autoimmune muscle diseases such as polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of inflammatory cells, production of cytokines and chemokines, as well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].